Transdermal delivery of insulin using a solid-in-oil nanodispersion enhanced by arginine-rich peptides

Tahara, Yoshiro; Honda, Shota; Kamiya, Noriho; Goto, Masahiro

doi:10.1039/c2md20059g

Cited by 24 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, HRP and lysozyme maintained > 90% of enzymatic activities in the S/O particles for 24 h, showing a high potency of the S/O nanodispersion as a protein carrier for the transdermal drug delivery . The transdermal delivery of insulin was improved by co‐encapsulation of oligoarginines . Recent research has revealed that there are tight junctions between epithelial cells that act as the second physical barrier to protect from infiltration of pathogens and endotoxins .…”

Section: Application Of S/o Nanodispersion Systemsmentioning

confidence: 99%

Solid‐in‐oil nanodispersions for transdermal drug delivery systems

Kitaoka

Wakabayashi

Kamiya

et al. 2016

Biotechnology Journal

Self Cite

View full text Add to dashboard Cite

Transdermal administration of drugs has advantages over conventional oral administration or administration using injection equipment. The route of administration reduces the opportunity for drug evacuation before systemic circulation, and enables long‐lasting drug administration at a modest body concentration. In addition, the skin is an attractive route for vaccination, because there are many immune cells in the skin. Recently, solid‐in‐oil nanodisperison (S/O) technique has demonstrated to deliver cosmetic and pharmaceutical bioactives efficiently through the skin. S/O nanodispersions are nanosized drug carriers designed to overcome the skin barrier. This review discusses the rationale for preparation of efficient and stable S/O nanodispersions, as well as application examples in cosmetic and pharmaceutical materials including vaccines. Drug administration using a patch is user‐friendly, and may improve patient compliance. The technique is a potent transcutaneous immunization method without needles.

show abstract

Section: Application Of S/o Nanodispersion Systemsmentioning

confidence: 99%

Solid‐in‐oil nanodispersions for transdermal drug delivery systems

Kitaoka

Wakabayashi

Kamiya

et al. 2016

Biotechnology Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a preliminary study, we examined surfactant protein ratios of 1:25, 1:50, and 1:100, and we found that the nanodispersion was unstable when the ratio was 1:25. As higher surfactant concentrations were prone to inhibiting the protein permeation through the skin [19][20][21], we employed a surfactant:protein ratio of 1:50 for preparing the S/O nanodispersions in this study. The mean particle size of the S/O dispersions used here was around 300 nm.…”

Section: Discussionmentioning

confidence: 99%

A Solid-in-Oil Nanodispersion System for Transcutaneous Immunotherapy of Cow’s Milk Allergies

et al. 2020

Self Cite

View full text Add to dashboard Cite

An allergy to cow’s milk proteins is the most common food allergy in infants and toddlers. Conventional oral immunotherapy for cow’s milk allergies requires hospital admission due to the risk of severe allergic reactions, including anaphylaxis. Therefore, a simpler and safer immunotherapeutic method is desirable. We examined transcutaneous immunotherapy with a solid-in-oil (S/O) system. In the S/O system, nano-sized particles of proteins are dispersed in an oil-vehicle with the assistance of nonionic surfactants. In the present study, the S/O system enhanced the skin permeation of the allergen molecule β-lactoglobulin (BLG), as compared with a control PBS solution. The patches containing BLG in the S/O nanodispersion skewed the immune response in the allergy model mice toward T helper type 1 immunity, indicating the amelioration of allergic symptoms. This effect was more pronounced when the immunomodulator resiquimod (R-848) was included in the S/O system.

show abstract

“…Moreover, the effects of addition or covalent modification by PEG or cyclodextrins were investigated using ␣ or ␥-chymotrypsin as model proteins (Castellanos et al, , 2005a(Castellanos et al, , 2005b(Castellanos et al, , 2006Castellanos and Griebenow, 2003;Perez et al, 2002). A similar method has been used to prepare a PLGA microsphere containing vascular endothelial growth factor (Kim and Burgess, 2002), human growth hormone (hGH) (Takada et al, 2003), insulin (Kang and Singh, 2005;Andreas et al, 2011), immunoglobulin G (Wang et al, 2004), glial cell linederived neurotrophic factor (Checa-Casalengua et al, 2011), typical model proteins such as lysozyme, ␣-chymotrypsin, peroxidase and ␤-galactosidase (Giteau et al, 2008), BSA-loaded calcium phosphate nanoparticles (Pitukmanorom et al, 2008), BSA-loaded dextran glassy particles (Yuan et al, 2010), recombinant human granulocyte colony-stimulating factor-loaded glassy sodium hyaluronate particles (Wu et al, 2011), recombinant human erythropoietin and human serum albumin mixture microparticles (He et al, 2011), BSA-or ␤-galactosidasen-loaded dextran nanoparticles , BSA-loaded porous silicon microparticles (Fan et al, 2011) and zinc-BSA nanoparticles (Ma et al, 2012). In these procedures, proteins or protein-loaded particles were directly dispersed into the oil phase to form S/O suspensions.…”

Section: )mentioning

confidence: 99%